ERBB2 and breast carcinoma: analyzed genomic data from 523 Chinese female breast cancer patients and reported that mutations in PIK3CA and genes associated with the PI3K‐Akt signaling pathway were more common in HER2‐low breast cancer patients, whereas mutations in TP53 were more common in HER2‐negative cancer patients [6].